Employees: 3,200
Size WELL Health Technologies (WELL.TO) is a Canada Health Care company (Medical/Nursing Services) with a market value of $661M, the 289th largest of 405 Canada companies the cockpit tracks. Shares closed at C$3.70 on 18 Nov 2026.
Performance Over six months the shares fell 8.9%, against -6.2% for the median peer and +1.1% for the Canada market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 29.1% over the last twelve months (peer median +5.2%); the operating margin is 6.3% (peer median 7.5%).
Valuation It trades at 10.1× forward earnings against a peer median of 19.8× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -84 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.6 points below its cost of capital (7.3% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$1.56B | C$1.40B | C$920M | C$776M | C$569M |
| Revenue growth | — | +52% | +19% | +36% | — |
| Gross profit | C$590M | C$525M | C$291M | C$311M | C$248M |
| EBITDA | C$205M | C$207M | C$52.9M | C$102M | C$81.7M |
| Net income | -C$129M | -C$7.36M | C$32.6M | C$82,000 | C$1.37M |
| Free cash flow | C$66.0M | C$87.9M | -C$10.6M | C$37.2M | C$65.7M |
| Capital expenditure | C$40.7M | C$27.9M | C$16.2M | C$25.4M | C$6.62M |
| Total debt | C$909M | C$711M | C$473M | C$426M | C$358M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WELL.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.9% | +1.0% | 6th lowest of 21 |
| 6-month return | -8.9% | -6.2% | 10th lowest of 21 |
| Distance from 52-week high | -28.7% | -35.4% | 10th highest of 21 |
| Revenue growth (TTM) | +29.1% | +5.2% | 4th highest of 21 |
| Operating margin | 6.3% | 7.5% | 9th lowest of 21 |
| Forward P/E | 10.1× | 19.8× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 10.1% | 7.5% | 8th most demanding of 17 |
| Growth delivered (Del g) | +94.5% | +9.5% | highest of 17 |
| Hurdle (Req g minus delivered) | -84.5 pp | -1.2 pp | least demanding of 17 |
| ROIC minus cost of capital | -3.6 pp | -0.3 pp | 7th lowest of 20 |
| EV / EBITDA | 9.2× | 8.0× | 7th most expensive of 15 |
| Net debt / EBITDA | 3.4× | 1.6× | 4th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 12.3× | -4.7% | +12.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |